Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1059Stomach Neoplasms 803Carcinoma, Hepatocellular 785Pancreatic Neoplasms 577Rectal Neoplasms 450Colonic Neoplasms 405Esophageal Neoplasms 363Liver Neoplasms 225Esophageal Squamous Cell Carcinoma 144Neoplasms 134Cholangiocarcinoma 129Neoplasm Metastasis 118Breast Neoplasms 117Gastrointestinal Neoplasms 106Lung Neoplasms 76Biliary Tract Neoplasms 73Recurrence 61Prostatic Neoplasms 52Ovarian Neoplasms 49Barrett Esophagus 47Carcinoma, Non-Small-Cell Lung 44Anastomotic Leak 43Bile Duct Neoplasms 42Gastrointestinal Stromal Tumors 40Gallbladder Neoplasms 40Head and Neck Neoplasms 38Digestive System Neoplasms 36Anus Neoplasms 34Colonic Polyps 33Adenocarcinoma Of Esophagus 32

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Resectable Biliary Tract Cancer × Gastrointestinal × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡